Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
REGULATORY
Japan OKs 1st DPP-4 Generic for Januvia, Zytiga Draws 6 Entrants towards December Listing
Japan approved the first generic version of a DPP-4 inhibitor for MSD’s Januvia (sitagliptin) on August 15 along with a throng of other products that had been filed towards the next biannual generic listing in December. Janssen’s cancer agent Zytiga…
To read the full story
Related Article
- Sawai’s Revlimid Generic, BMS’ AG Now Available; Trerief AG Launch Set for Feb. 20
December 8, 2023
- First Generics for 5 APIs to Join NHI Price List; No Entries for Januvia, Zytiga
December 7, 2023
- Merck Sues Sawai over Januvia Generics Approved in Japan
October 27, 2023
- Solo Januvia Generic Approval Likely Exploited Patent Loophole, Litigation Possible?
August 18, 2023
- BMS Unit Wins Japan Approval for Sprycel Authorized Generic
August 17, 2023
REGULATORY
- Sakigake Tag Granted for Iclepertin, Brogidirsen
November 28, 2024
- DPP Confirms Plan to Urge 4 Ministers to Scrap Off-Year Price Revisions
November 28, 2024
- MHLW Seeks Comments on Rx-to-OTC Switch of Tadalafil, 2 Other APIs
November 27, 2024
- JPMA Calls for Legal Framework to Facilitate Use of Pseudonymized Data
November 27, 2024
- Japan Likely to Extend “Catch-Up” HPV Vaccination Program
November 26, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…